Pfizer Inc (PFE) - Total Assets
Based on the latest financial reports, Pfizer Inc (PFE) holds total assets worth $208.73 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Pfizer Inc shareholders equity for net asset value and shareholders' equity analysis.
Pfizer Inc - Total Assets Trend (1985–2024)
This chart illustrates how Pfizer Inc's total assets have evolved over time, based on quarterly financial data.
Pfizer Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Pfizer Inc's total assets of $208.73 Billion consist of 23.6% current assets and 76.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $1.04 Billion | 0.5% |
| Accounts Receivable | $14.78 Billion | 6.9% |
| Inventory | $10.85 Billion | 5.1% |
| Property, Plant & Equipment | $20.68 Billion | 9.7% |
| Intangible Assets | $55.41 Billion | 26.0% |
| Goodwill | $68.53 Billion | 32.1% |
Asset Composition Trend (1985–2024)
This chart illustrates how Pfizer Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Pfizer Inc (PFE) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pfizer Inc's current assets represent 23.6% of total assets in 2024, a decrease from 48.4% in 1985.
- Cash Position: Cash and equivalents constituted 0.5% of total assets in 2024, down from 9.3% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 57.0% of total assets, an increase from 2.0% in 1985.
- Asset Diversification: The largest asset category is goodwill at 32.1% of total assets.
Pfizer Inc Competitors by Total Assets
Key competitors of Pfizer Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.07 Billion |
|
Novartis AG
MX:NVSN
|
Mexico | MX$110.95 Billion |
|
Novartis AG ADR
NYSE:NVS
|
USA | $115.57 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$208.73 Billion |
|
Virbac SA
PA:VIRP
|
France | €1.82 Billion |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019
|
China | CN¥13.11 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$1.83 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$112.48 Billion |
Pfizer Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.28 | 1.00 | 1.35 |
| Quick Ratio | 0.97 | 0.73 | 1.04 |
| Cash Ratio | 0.04 | 0.03 | 0.00 |
| Working Capital | $10.33 Billion | $12.00 Million | $9.15 Billion |
Pfizer Inc - Advanced Valuation Insights
This section examines the relationship between Pfizer Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.69 |
| Latest Market Cap to Assets Ratio | 0.70 |
| Asset Growth Rate (YoY) | -5.8% |
| Total Assets | $213.40 Billion |
| Market Capitalization | $149.70 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Pfizer Inc's assets below their book value (0.70x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Pfizer Inc's assets decreased by 5.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Pfizer Inc (1985–2024)
The table below shows the annual total assets of Pfizer Inc from 1985 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $213.40 Billion | -5.79% |
| 2023-12-31 | $226.50 Billion | +14.86% |
| 2022-12-31 | $197.21 Billion | +8.67% |
| 2021-12-31 | $181.48 Billion | +17.67% |
| 2020-12-31 | $154.23 Billion | -7.92% |
| 2019-12-31 | $167.49 Billion | +5.06% |
| 2018-12-31 | $159.42 Billion | -7.20% |
| 2017-12-31 | $171.80 Billion | +0.11% |
| 2016-12-31 | $171.62 Billion | +2.48% |
| 2015-12-31 | $167.46 Billion | -1.07% |
| 2014-12-31 | $169.27 Billion | -1.64% |
| 2013-12-31 | $172.10 Billion | -7.37% |
| 2012-12-31 | $185.80 Billion | -1.17% |
| 2011-12-31 | $188.00 Billion | -3.60% |
| 2010-12-31 | $195.01 Billion | -8.42% |
| 2009-12-31 | $212.95 Billion | +91.59% |
| 2008-12-31 | $111.15 Billion | -3.57% |
| 2007-12-31 | $115.27 Billion | +0.38% |
| 2006-12-31 | $114.84 Billion | -2.32% |
| 2005-12-31 | $117.56 Billion | -4.95% |
| 2004-12-31 | $123.68 Billion | +5.92% |
| 2003-12-31 | $116.78 Billion | +151.91% |
| 2002-12-31 | $46.36 Billion | +18.40% |
| 2001-12-31 | $39.15 Billion | +16.84% |
| 2000-12-31 | $33.51 Billion | +62.88% |
| 1999-12-31 | $20.57 Billion | +12.41% |
| 1998-12-31 | $18.30 Billion | +19.34% |
| 1997-12-31 | $15.34 Billion | +4.56% |
| 1996-12-31 | $14.67 Billion | +15.22% |
| 1995-12-31 | $12.73 Billion | +14.69% |
| 1994-12-31 | $11.10 Billion | +18.94% |
| 1993-12-31 | $9.33 Billion | -2.70% |
| 1992-12-31 | $9.59 Billion | -0.46% |
| 1991-12-31 | $9.63 Billion | +6.44% |
| 1990-12-31 | $9.05 Billion | +8.74% |
| 1989-12-31 | $8.32 Billion | +9.00% |
| 1988-12-31 | $7.64 Billion | +10.33% |
| 1987-12-31 | $6.92 Billion | +34.06% |
| 1986-12-31 | $5.16 Billion | +15.70% |
| 1985-12-31 | $4.46 Billion | -- |
About Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevna… Read more